



ASX ANNOUNCEMENT  
28<sup>th</sup> of February 2019

APPENDIX 4D

---

**Results for Announcement to the Market**

**Key Information**

	Half-year Ended 31 December 2018 \$'000	Half-year Ended 31 December 2017 \$'000	% Change
Revenue from ordinary activities	174	-	100
Loss from ordinary activities	(2,366)	(106)	2,132

**Dividends Paid and Proposed**

There were no paid or proposed dividends for the half-year ended 31 December 2018.

**Explanation of Key Information and Dividends**

An explanation of the above figures is contained in the "Review of Operations" included within the attached directors' report.

**Net Tangible Assets per Share**

	Half-year Ended 31 December 2018 \$/Share	Half-year Ended 31 December 2017 \$/Share
Net tangible assets per share	\$0.11	\$261.33

Althea issued 203,310,000 shares in September 2018 as part of the capital raise. Therefore, the 31 December 2017 results are impacted by the limited numbers of shares on issue at that time.

**Dividend Reinvestment Plans**

The Group does not have any dividend reinvestment plans in operation.

**Audit review**

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

-ENDS-

**About Althea**

Althea Group Holdings Limited (ASX:AGH) is a patient-focused medicinal cannabis company that has all the required licenses and permits to import, cultivate, produce and supply medicinal cannabis in Australia.

Through a strategic partnership with cornerstone investor Aphria Inc., one of the largest cannabis companies listed in North America, Althea has become a leading supplier of medicinal cannabis in the Australian market.



Althea's focus on patient care underpins its business strategy. To this end, Althea has developed a mobile application and web-based platform to educate healthcare professionals on the benefits of medicinal cannabis and assist them in navigating the regulatory landscape. Althea is currently planning the construction of its own production facility and is in the process of expanding its product portfolio, patient numbers, and global footprint.

To learn more please visit: [www.althea.com.au](http://www.althea.com.au)

**Althea:**

**Josh Fegan, CEO & Managing Director**

1300 70 20 20 | [contact@althea.com.au](mailto:contact@althea.com.au)

**Investors:**

**PAC Partners Securities**

03 8633 9834 | [enquiries@pacpartners.com.au](mailto:enquiries@pacpartners.com.au)

**Media contacts:**

**The Capital Network**

Julia Maguire, Executive Director

0419 815 386 | [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)